Tyers Asset Management LLC cut its stake in Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) by 40.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,044 shares of the company’s stock after selling 1,400 shares during the period. Tyers Asset Management LLC’s holdings in Y-mAbs Therapeutics were worth $47,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. BNP Paribas Arbitrage SA bought a new stake in shares of Y-mAbs Therapeutics during the first quarter worth approximately $38,000. Bank of Montreal Can bought a new stake in shares of Y-mAbs Therapeutics during the second quarter worth approximately $39,000. Bank of America Corp DE raised its stake in shares of Y-mAbs Therapeutics by 3,056.5% during the fourth quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after buying an additional 5,838 shares during the last quarter. Deutsche Bank AG bought a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth approximately $191,000. Finally, Swiss National Bank bought a new stake in shares of Y-mAbs Therapeutics during the second quarter worth approximately $290,000. 32.06% of the stock is owned by institutional investors.
A number of research firms recently weighed in on YMAB. Zacks Investment Research raised shares of Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Cowen reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Monday, July 1st. Wedbush began coverage on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 3rd. They set an “outperform” rating and a $38.00 price target for the company. Finally, HC Wainwright set a $40.00 price target on shares of Y-mAbs Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 26th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $32.50.
Shares of YMAB traded down $0.48 on Friday, reaching $29.67. 232,037 shares of the company’s stock were exchanged, compared to its average volume of 154,199. The company has a current ratio of 9.04, a quick ratio of 9.04 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.03 billion and a P/E ratio of -19.78. The business has a 50 day moving average price of $25.50 and a two-hundred day moving average price of $23.50. Y-mAbs Therapeutics, Inc has a 12 month low of $15.17 and a 12 month high of $31.00.
Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.05). Equities research analysts predict that Y-mAbs Therapeutics, Inc will post -2.1 EPS for the current year.
In related news, Chairman Thomas Gad sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $25.77, for a total transaction of $103,080.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Johan Wedell-Wedellsborg sold 17,243 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $27.00, for a total transaction of $465,561.00. In the last 90 days, insiders have sold 348,010 shares of company stock valued at $9,378,508. Corporate insiders own 38.40% of the company’s stock.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Read More: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.